Sharecare launches self-service software platform to enable independent decentralized clinical research

The next generation of Smart Omix by Sharecare presents a scalable SaaS-based solution to enable independent researchers, clinicians and academic institutions to conduct digital research studies

ATLANTE, September 6, 2022 /PRNewswire/ — Sharecare (Nasdaq: SHCR), the digital health company that helps people manage all of their health in one place, today announced the evolution of Sharecare Smart Omix, its proprietary digital clinical research solution that enables real-world data collection and digital biomarker creation through mobile research studies. By expanding the capabilities of Smart Omix, Sharecare not only broadens the scope of its life science opportunities beyond the point of commercialization, but also plays an important role in improving relevance, equity and data integrity in clinical research across the healthcare continuum.

Building on Sharecare’s work with leading life science companies to conduct decentralized custom research studies, the intuitive new software-as-a-service (SaaS) platform is purpose-built to overcome technology barriers, economics and talent to remote observational studies more commonly encountered by members of the research community, particularly clinicians and underserved independent and academic researchers. The Smart Omix web-based platform is a no-code solution that gives researchers the ability to conduct studies independently. allowing them to design, launch, manage and analyze clinical studies through a simple and easily accessible self-service interface, and eliminating the need for design and engineering expertise to build and launch their studies.

“Smart Omix is ​​designed for researchers by researchers to make high-quality, rigorous real-world data studies an accessible reality across the field – whether conducted within a pharmaceutical company or by a “citizen scientist” aiming to learn more about a condition said Zeenia Framroze, Sharecare Vice President of Strategy and Operations for Smart Omix. “By combining a SaaS model and decentralized research methodologies, Smart Omix has untapped and exceptional potential to help democratize research in a digitally driven world.”

With a tiered license Price model, Smart Omix enables all researchers – clinicians, academics, students, and scientists – to implement a cost-effective solution that meets their independent research needs – from prototyping a study to Institutional Review Board approval to complete execution of a clinical study – for any length of time. Within the self-service platform, easy-to-use tools enable researchers to establish and manage electronic informed consent (eConsent) and membership-based compensation processes, create and refine study protocols and collect electronic patient-reported results (ePRO). Studies can be initiated with participants through the companion app, Smart Omix by Sharecare – available for download in the App store and google play – which allows researchers to conduct their studies and collect rich real-world data via a smartphone.

By decentralizing clinical research, Smart Omix replaces physical trial sites, capitalizing on the efficiency and scalability of digital studies while addressing socio-economic barriers to patient and consumer engagement, such as transportation needs and time away from work. The platform also supports a seamless and user-friendly participant experience that engages individuals as they use their own devices to self-report and visualize their data, while allowing them to observe their own day-to-day health metrics. day and, with their consent, inform their healthcare teams of their state of health. To date, leading pharmaceutical and life science companies, including UCB, have used Smart Omix to advance relevance, fairness and data integrity in research on various disease states through studies on smartphone-based measurement.

“At UCB, our ambition is to deliver targeted solutions that can improve outcomes for people living with rare diseases, and real-world research – especially in these small patient populations – is essential,” said Colin Lake, Global Head of Digital Transformation, Neurology, at UCB. “We originally asked Sharecare to conduct a custom study using Smart Omix on mobile devices to see how we could develop objective symptom measures for people with myasthenia gravis, a rare neuromuscular disease. We commend them for the public release of the full Smart Omix platform.

For more information on conducting research studies with Smart Omix by Sharecare, visit sharecare.com/smartomix.

About ShareCare

Sharecare is the leading digital health company helping people, wherever they are on their health journey, unify and manage all of their health in one place. Our comprehensive, data-driven virtual health platform is designed to help individuals, providers, employers, health plans, government organizations, and communities optimize individual and population-wide wellness promoting positive behavior change. Driven by our philosophy that we are all better together, at Sharecare we are committed to supporting each individual through the lens of their personal health and to making high-quality care more accessible and affordable for everyone. To learn more, visit www.sharecare.com.

Media Contact:
Sharecare Public Relations Team
[email protected]
404.665.4305

SOURCE Sharecare

Veronica J. Snell